A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Not Recruiting

Trial ID: NCT01248949


To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.

Official Title

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

Stanford Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD

Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery

Lawrence Recht, MD
Lawrence Recht, MD

Professor of Neurology and, by courtesy, of Neurosurgery


Inclusion Criteria:

   - Patients with confirmed diagnosis of advanced solid tumors (dose-escalation phase) or
   another solid tumor type based on antitumoral activity (dose-expansion phase) that are
   not responsive to standard therapy or for which no standard therapy exists

   - Patients must be 18 years of age or older

   - Karnofsky Performance Status ≥ 70

   - Toxicities from previous cancer therapies must have recovered to CTCAE Grade = or < 2

   - Adequate organ and marrow function

   - Using adequate contraceptive measures, be surgically sterile or post-menopausal

Exclusion Criteria:

   - Concurrently enrolled in another clinical study, except for non-interventiona
   observational studies, or if in a follow up period from a previous study

   - Receipt of any investigational anticancer therapy within 30 days prior to the first
   dose of MEDI3617, or in the case of monoclonal antibodies (eg, bevacizumab), 42 days
   prior to the first dose of MEDI3617

   - Current or previous treatment with angiopoietin inhibitors, or inhibitors of Tie1 or
   Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820

   - Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy
   for cancer treatment

   - Use of immunosuppressive medication or systemic steroids within 7 days prior to first
   dose of MEDI3617

   - Any condition that, in the opinion of the investigator, would interfere with
   evaluation of the investigational product or interpretation of subject safety or study

   - Known bleeding diathesis

   - Pulmonary hemorrhage or gross hemoptysis within 6 months prior to enrollment

   - Therapeutic or palliative radiation therapy within 2 weeks prior to enrollment


drug: MEDI3617

drug: Bevacizumab

drug: Paclitaxel

drug: Carboplatin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.